LBA1: DESTINY-Breast05: T-DXd significantly improves IDFS and DFS versus T-DM1 in HER2-positive early breast cancer with residual invasive disease

ESMO 2025

Breast Cancer

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

CHICAGO 2025

Gastrointestinal Cancer

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

ESMO 2025

Breast Cancer

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

ESMO 2025

Breast Cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

Breast Cancer

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

Int J Cancer

Beierlein M, Häberle L, Nabieva N, Maass N, Aktas B, Kümmel S, Thomssen C, Wolf C, Kolberg HC, Brucker C, Janni W, Dall P, Schneeweiss A, Marme F, Sütterlin MW, Ruebner M, Theuser AK, Hofmann NM, Böhm S, Almstedt K, Kellner S, Gass P, Lück HJ, Hein A, Schmatloch S, Kalder M, Uleer C, Juhasz-Böss I, Hanf V, Jackisch C, Müller V, Rack B, Belleville E, Wallwiener D, Rody A, Rauh C, Bayer CM, Uhrig S, Huebner H, Goossens C, Brucker SY, Hack CC, Fehm TN, Fasching PA

doi: 10.1002/ijc.70037

ESMO 2025

Breast Cancer

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

SABCS 2024

Breast Cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

SABCS 2024

Breast Cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

Breast Cancer

Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond

healthbook TIMES Onco Hema

Vetter M, Kurzeder C

doi: 10.36000/HBT.OH.2025.24.183

Related content

DESTINY-Breast11: Neoadjuvant T-DXd plus THP significantly improves pCR in high-risk HER2-positive early breast cancer

LBA4002: DESTINY-Gastric04: Improved OS with second-line T-Dxd versus ramucirumab plus paclitaxel in patients with HER2-positive metastatic GC/GEJA

DESTINY-Breast09: T-DXd plus placebo shows superior efficacy over THP across subgroups in HER2-positive advanced or metastatic breast cancer

monarchE: Adjuvant abemaciclib plus ET significantly improves OS in high-risk HR-positive, HER2-negative early breast cancer

Invasive disease-free and overall survival after (neo)adjuvant chemotherapy in postmenopausal patients with hormone receptor-positive, HER2-negative early breast cancer treated with upfront letrozole: Experiences from the phase IV PreFace trial

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer

OlympiA: Olaparib continues to demonstrate improved OS, IDFS and DDFS in patients with BRCA1/2-mutated HER2-negative high-risk early breast cancer

EMBER-3: Imlunestrant significantly improves PFS in patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations

Fourth Swiss Annual Meeting on HER2-Positive Breast Cancer: Antibody-Drug Conjugates in HER2-Positive Disease and Beyond